Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/17/2003EP1371647A2 Pyridine-3-carboxylic acid derivatives and their use as intermediates
12/17/2003EP1371646A1 Aryl-substituted alicyclic compound and medical composition comprising the same
12/17/2003EP1371373A1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
12/17/2003EP1371367A1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
12/17/2003EP1370685A2 Diagnosis of diseases associated with dna repair
12/17/2003EP1370684A2 Polynucleotides related to colon cancer
12/17/2003EP1370673A1 Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
12/17/2003EP1370662A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
12/17/2003EP1370661A2 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
12/17/2003EP1370659A2 Proteins, polynucleotides encoding them and methods of using the same
12/17/2003EP1370655A2 Secreted human proteins
12/17/2003EP1370647A2 A dna molecule encoding a variant paraoxonase and uses thereof
12/17/2003EP1370643A1 Method of extracting virus from cell culture
12/17/2003EP1370641A2 Use of stem cells and cd6-depleted stem cells for inducing tolerance of allogenic transplants and/or for treating leukaemia
12/17/2003EP1370588A2 Human monoclonal antibodies to fc alpha receptor (cd89)
12/17/2003EP1370587A2 Antiangiogenic peptides derived from endostatin
12/17/2003EP1370586A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370584A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370580A2 A new essential downstream component of the wingless signalling pathway
12/17/2003EP1370562A1 Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
12/17/2003EP1370560A1 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
12/17/2003EP1370556A1 Metalloproteinase inhibitors
12/17/2003EP1370555A1 Compounds derived from oxindoles and the use thereof in cancerology
12/17/2003EP1370554A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
12/17/2003EP1370553A2 Rho-kinase inhibitors
12/17/2003EP1370552A2 Rho-kinase inhibitors
12/17/2003EP1370546A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications
12/17/2003EP1370544A1 Nitric oxide donors based on metallic centres
12/17/2003EP1370539A1 Hiv inhibiting n-aminoimidazole derivatives
12/17/2003EP1370538A1 Metalloproteinase inhibitors
12/17/2003EP1370537A1 Metalloproteinase inhibitors
12/17/2003EP1370536A1 Metalloproteinase inhibitors
12/17/2003EP1370535A1 Metalloproteinase inhibitors
12/17/2003EP1370534A1 Metalloproteinase inhibitors
12/17/2003EP1370527A1 Indolone derivatives having vascular-damaging activity
12/17/2003EP1370526A1 Diamides which inhibit tryptase and factor xa activity
12/17/2003EP1370523A1 Diphenyl derivatives
12/17/2003EP1370522A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
12/17/2003EP1370301A2 Actinium-225 complexes and conjugates for targeted radiotherapy
12/17/2003EP1370298A1 Elongated and multiple spacers in activatible prodrugs
12/17/2003EP1370297A2 Method and composition
12/17/2003EP1370292A1 Use of cd23 antagonists for the treatment of neoplastic disorders
12/17/2003EP1370290A2 Molecular antigen array
12/17/2003EP1370289A2 Method for producing a vaccine containing autologous antibodies
12/17/2003EP1370280A2 Stabilized interleukin 2
12/17/2003EP1370277A1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
12/17/2003EP1370276A2 Medical uses of intercellular communication facilitating compounds
12/17/2003EP1370274A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases
12/17/2003EP1370271A2 A process for the manufacture of a herbal composition comprising a matrine
12/17/2003EP1370270A2 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
12/17/2003EP1370260A2 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
12/17/2003EP1370255A2 Cdc25 phosphatase inhibitors
12/17/2003EP1370250A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
12/17/2003EP1370249A1 Novel dendriticpolymers and their biomedical uses
12/17/2003EP1370144A1 Noninvasive measurements of chemical substances
12/17/2003EP1283842B1 Radiopharmaceutical products suitable for the selective labeling of lymphocytes, and their preparation
12/17/2003EP1272470B1 Amorphous torasemide modification
12/17/2003EP1206467B1 N-heterocyclic derivatives as nos inhibitors
12/17/2003EP1157031B1 Oligomers substituted by phosphonic acid ester, phosphonic acid or carbaborane functions and the corresponding pna monomers
12/17/2003EP1150692B1 Use of hyaluronic acid or fragments thereof for the preparation of a medicament for regulating hematopoietic differentiation
12/17/2003EP1142900B1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same
12/17/2003EP1109799B1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
12/17/2003EP1093456B1 Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
12/17/2003EP1082302B1 A vla-4 inhibitor: omepupa-v
12/17/2003EP1009420B1 Conjugates useful in the treatment of prostate cancer
12/17/2003EP0934276B1 Anthranilic acid derivatives as multi drug resistance modulators
12/17/2003EP0839154B1 Biologically active peptides and compositions, their use
12/17/2003EP0571387B1 A non-mitogenic competitive hgf antagonist
12/17/2003CN1462276A Peptide-based compounds
12/17/2003CN1462274A Triazolo-epothilones
12/17/2003CN1461806A Human leukemia related reverse transcript virus gene genome nucleic acid sequence and its application
12/17/2003CN1461752A Humon leukemia related reverse transcrigt virus genome coded protein and polypeptide sequence and its application
12/17/2003CN1461644A Medicine for treating lung cancer-Bofeng capsule, and art for producing same
12/17/2003CN1131309C IL-6 mutein
12/17/2003CN1131239C Compositions for treating or preventing prostatic cancer
12/17/2003CN1131234C Antisense nuleic acid against protein kinase gene and its tumor-inhibiting function
12/17/2003CN1131228C Benzo (5,6) cyclohepta (1,2-6) pyridine derivs. for inhibition of farnesy-protein transferase
12/17/2003CN1131224C Luteolin and method for preparationg luteolin derivatives
12/17/2003CN1131216C Condensed 1,2-indene dihydride and its salt for medicine its preparation method and application
12/17/2003CN1131072C Radioactive chitosan complex, its preparation method and use
12/17/2003CN1131036C Application of N-acefyl-D-aminoglucose in preparing medicines to suppress by-effect of radiotherapy and chemicotherapy
12/16/2003US6664395 Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia
12/16/2003US6664389 Highly resistant granular starch
12/16/2003US6664288 Method and composition for the treatment of cancer
12/16/2003US6664285 Use of cell membrane penetrating indigoid bisindole derivatives
12/16/2003US6664275 C10 heterosubstituted acetate taxanes
12/16/2003US6664272 Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue
12/16/2003US6664269 Isoquinolinone derivatives
12/16/2003US6664264 Thioether substituted imidazoquinolines
12/16/2003US6664263 1,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activity
12/16/2003US6664255 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
12/16/2003US6664247 Pyrazole compounds useful as protein kinase inhibitors
12/16/2003US6664246 > 1 x 10-7 mole per liter of a vitamin D compound in an acceptable lipid; anticancer agents
12/16/2003US6664242 Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer
12/16/2003US6664229 Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72
12/16/2003US6664105 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
12/16/2003US6664040 Complexing to polypeptides; antiproliferation agent
12/16/2003US6663900 Processed in a fluidized bed coating machine where a protective coating of a sugar or polyhydric alcohol, starch
12/16/2003US6663871 Non-replicating or replication- impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition, malaria
12/16/2003US6663858 Antitumor, gene therapy
1 ... 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 ... 2211